Certified Regulatory Affairs Professional (CRAP) — Questions and Answers

Question 1: Under FDA regulations, what must appear on the principal display panel (PDP) of a drug product label?

Manufacturer contact information
Brand name only
Statement of identity and net quantity of contents (Correct answer)
List of inactive ingredients

Correct answer: Statement of identity and net quantity of contents

The PDP must include the statement of identity and net quantity of contents per FDA labeling requirements under 21 CFR Part 201.

Question 2: What is the regulatory classification of a product whose label contains false or unauthorized claims?

The product must be reformulated before sale
The product is considered adulterated
The product requires a mandatory boxed warning
The product is considered misbranded (Correct answer)

Correct answer: The product is considered misbranded

A product with false, misleading, or unauthorized labeling claims is considered misbranded under the FD&C Act and is subject to regulatory action.

Question 3: Under 21 CFR Part 7, what distinguishes a Class I recall from a Class II recall?

Class I requires public press release; Class II does not
Class I is voluntary; Class II is mandatory
Class I involves cosmetics; Class II involves drugs
Class I involves a reasonable probability of serious adverse health consequences; Class II involves remote probability (Correct answer)

Correct answer: Class I involves a reasonable probability of serious adverse health consequences; Class II involves remote probability

Class I recall involves a reasonable probability that use of the product will cause serious adverse health consequences or death, while Class II involves a remote probability of adverse consequences.

Question 4: What is the significance of professional networking in the Certified Regulatory Affairs Professional field?

It distracts from actual work
It facilitates knowledge exchange, referrals, and collaborative problem-solving (Correct answer)
It is only useful for finding new employment
It is only important early in one's career

Correct answer: It facilitates knowledge exchange, referrals, and collaborative problem-solving

Professional networking facilitates knowledge exchange, generates referrals, and enables collaborative problem-solving that improves practice quality.

Question 5: What is the primary purpose of a 'no-action letter' in regulatory practice?

To delay implementation of a final rule
To dismiss a citizen petition
To commit an agency to not take enforcement action on a specific practice (Correct answer)
To formally prohibit a regulated entity's proposed activity

Correct answer: To commit an agency to not take enforcement action on a specific practice

A no-action letter is an agency commitment to refrain from enforcement against a specific entity for a described practice under stated conditions.

Question 6: What is a 'reminder advertisement' in pharmaceutical promotion?

An annual reminder of a drug's approved indications sent to physicians
A follow-up ad sent after a new product launch
An ad that names a drug but makes no efficacy or safety claims about it (Correct answer)
An ad that reminds patients to take medication as directed

Correct answer: An ad that names a drug but makes no efficacy or safety claims about it

A reminder advertisement names a drug but makes no claims about it, which exempts it from the fair balance requirement for presenting risk information.

Question 7: What is design control?

Marketing slogan.
Public relations outline.
Process of managing design and verification (Correct answer)
Production checklist.

Correct answer: Process of managing design and verification

Design control is a systematic process used in product development, particularly for medical devices, to manage and document the design process from conception through transfer to production. It ensures that the design meets user needs and intended uses, and that all design inputs, outputs, reviews, verifications, and validations are properly controlled. This process is crucial for producing safe and effective products that comply with regulatory requirements.

Question 8: An EU-regulated medical device company updates its Quality Management System to comply with MDR 2017/745 (replacing MDD). What is the PRIMARY change management priority?

Apply for a transition period extension from the European Commission
Conduct a gap analysis between MDD requirements and MDR, then develop a remediation plan (Correct answer)
Withdraw products from the EU market until full MDR compliance is achieved
Immediately re-certify all products under MDD

Correct answer: Conduct a gap analysis between MDD requirements and MDR, then develop a remediation plan

A systematic gap analysis between existing MDD compliance and new MDR requirements is the essential first step to understanding what changes are needed and prioritizing remediation efforts.

Question 9: Under which regulation must medical device labels include a Unique Device Identifier (UDI)?

21 CFR Part 820
21 CFR Part 880
21 CFR Part 801
21 CFR Part 830 (Correct answer)

Correct answer: 21 CFR Part 830

21 CFR Part 830 establishes the UDI system requirements, mandating that medical device labels include a unique device identifier for traceability throughout the supply chain.

Question 10: During a Pre-IND meeting with the FDA, what is the most important communication objective for the regulatory affairs team?

To submit all preclinical and clinical data for agency review
To clearly present the proposed development program and obtain agency guidance on key scientific and regulatory questions (Correct answer)
To obtain binding commitments from the FDA on future approval timelines
To negotiate reduced user fees for the development program

Correct answer: To clearly present the proposed development program and obtain agency guidance on key scientific and regulatory questions

Pre-IND meetings aim to present the proposed development program and obtain FDA guidance on critical questions to inform the IND strategy and reduce development risk.

Question 11: What is the purpose of the 'Supplement Facts' panel required on dietary supplement labels?

To indicate FDA approval status
To provide dosing instructions for therapeutic use
To disclose serving size, ingredient amounts, and percent daily values (Correct answer)
To list the manufacturer's quality certifications

Correct answer: To disclose serving size, ingredient amounts, and percent daily values

The Supplement Facts panel, required under DSHEA, discloses serving size, ingredient amounts, and percent daily values for dietary supplements.

Question 12: What does 'fair balance' require in pharmaceutical advertising?

Presenting risks and benefits with comparable emphasis and prominence (Correct answer)
Equal airtime for brand and generic drugs
Balancing the number of ads for competing products
Ensuring equal representation of patient demographics

Correct answer: Presenting risks and benefits with comparable emphasis and prominence

Fair balance requires that risk information be presented with similar prominence and emphasis as benefit information in drug promotional materials.

Question 13: Which of the following constitutes a labeling violation under FDA regulations?

Including patient counseling information on drug labels
Listing all inactive ingredients on prescription drug labels
Including a toll-free number for adverse event reporting
Making a disease claim on a dietary supplement without FDA approval (Correct answer)

Correct answer: Making a disease claim on a dietary supplement without FDA approval

Dietary supplements cannot legally claim to diagnose, cure, treat, or prevent diseases without FDA approval, as such claims would classify them as drugs.

Question 14: In a regulated environment, a 'predicate rule' in the context of 21 CFR Part 11 refers to:

The initial FDA guidance document for a new product class
The underlying FDA regulation (e.g., 21 CFR Parts 211, 820) that requires the record to be kept (Correct answer)
The first SOP ever approved by a company
A rule governing how clinical trial data is randomized

Correct answer: The underlying FDA regulation (e.g., 21 CFR Parts 211, 820) that requires the record to be kept

Predicate rules are the specific FDA regulations that require certain records to be maintained; Part 11 governs the electronic format of those records.

Question 15: Which of the following best describes the role of regulatory affairs in cross-functional product development team meetings?

To approve all scientific decisions made by other functions
To serve as the primary liaison between the team and regulatory agencies, providing guidance on regulatory requirements and strategy (Correct answer)
To represent legal interests and manage intellectual property matters
To manage the clinical trial budget and resource allocation

Correct answer: To serve as the primary liaison between the team and regulatory agencies, providing guidance on regulatory requirements and strategy

Regulatory affairs professionals serve as the regulatory strategy resource and agency liaison within cross-functional teams, ensuring regulatory requirements shape development decisions.

Question 16: Which type of labeling change to an NDA requires a Prior Approval Supplement (PAS)?

Correcting a typographical error in inactive ingredient listing
Adding a new boxed warning based on post-market safety data (Correct answer)
Updating the product lot number format
Updating the manufacturer's address

Correct answer: Adding a new boxed warning based on post-market safety data

Adding a new boxed warning requires a Prior Approval Supplement because it represents a significant safety labeling change that must be reviewed and approved by FDA before implementation.

Question 17: What does NDA stand for in regulatory submissions?

National Drug Agreement
National Dosing Authority
Notice of Drug Allocation
New Drug Application (Correct answer)

Correct answer: New Drug Application

A New Drug Application (NDA) is a formal submission to the FDA by a pharmaceutical company seeking approval to market a new drug in the United States. The NDA contains all the scientific data and information about the drug, including its safety, effectiveness, manufacturing, and labeling, gathered during preclinical and clinical development. Approval of an NDA signifies that the drug is safe and effective for its intended use.

Question 18: Under the Medical Device Reporting (MDR) regulation (21 CFR Part 803), what events must manufacturers report to FDA?

Deaths, serious injuries, or malfunctions likely to cause death or serious injury if recurrent (Correct answer)
All device recalls regardless of the cause
All complaints received about a device regardless of severity
Any device returned by a customer for any reason

Correct answer: Deaths, serious injuries, or malfunctions likely to cause death or serious injury if recurrent

MDR regulations require manufacturers to report events where a device may have caused or contributed to death, serious injury, or a malfunction that could cause death or serious injury if it recurred.

Question 19: A company wants to implement a Corrective Action to address recurring Out-of-Specification (OOS) results. Before closing the CAPA, which documentation is REQUIRED under 21 CFR 211.192?

Batch release certificate signed by QP
Annual product review entry for the OOS event
FDA notification of OOS results within 15 days
Written record of the investigation including assignable cause and disposition decision (Correct answer)

Correct answer: Written record of the investigation including assignable cause and disposition decision

21 CFR 211.192 requires a written record of the laboratory investigation, including the cause of the OOS result if identified, and the disposition of the affected batch.

Question 20: Which metrics are most important for a comprehensive monitoring strategy?

Only CPU usage
Only user complaints
Availability, performance, error rates, and resource utilization (Correct answer)
Network bandwidth exclusively

Correct answer: Availability, performance, error rates, and resource utilization

A comprehensive strategy monitors availability, performance, error rates, and resource utilization together to provide complete visibility into system health.

Question 21: An FDA inspector observes during a PAI that a company's CAPA system contains 47 open CAPAs, many overdue by more than a year. This finding MOST likely indicates:

The company only opens CAPAs for critical issues, making each one complex
The CAPA system lacks adequate resources, timelines, and management oversight to ensure effective closure (Correct answer)
The company has a highly active problem-detection system
Open CAPAs are acceptable if the root cause is still under investigation

Correct answer: The CAPA system lacks adequate resources, timelines, and management oversight to ensure effective closure

Large numbers of overdue CAPAs are a classic indicator of a CAPA system that identifies problems but lacks the management commitment, resources, and tracking to resolve them effectively.

Question 22: During a continuous improvement review, a team finds that post-market change supplements consistently take longer to prepare than industry benchmarks. The MOST effective process improvement would be to:

Hire additional regulatory writers to increase capacity
Implement a change impact classification system and pre-approved templates for common change types (Correct answer)
Reduce the frequency of changes to minimize supplement workload
Negotiate faster FDA review timelines through more frequent agency meetings

Correct answer: Implement a change impact classification system and pre-approved templates for common change types

A classification system with pre-approved templates for common change types reduces rework, ensures completeness, and allows regulatory staff to focus effort on novel complex changes.

Question 23: Which statement about electronic signatures under 21 CFR Part 11 is CORRECT?

Electronic signatures require annual re-certification by the FDA
Only C-suite executives may use electronic signatures on regulatory documents
An electronic signature does not carry the same legal weight as a handwritten signature
Electronic signatures must be linked to their respective electronic records and cannot be copied or transferred (Correct answer)

Correct answer: Electronic signatures must be linked to their respective electronic records and cannot be copied or transferred

21 CFR Part 11.70 requires that electronic signatures be permanently linked to their associated records to prevent falsification through copying.

Question 24: During the Design Control process under 21 CFR Part 820, which document formally captures the intended use and user needs before design specifications are written?

Design Input requirements (Correct answer)
Design Validation protocol
Design History File
Device Master Record

Correct answer: Design Input requirements

Design Input requirements translate user needs and intended use into specific technical requirements before the design process begins.

Question 25: An FDA Warning Letter cites a company for failure to investigate consumer complaints that could indicate product adulteration. Under 21 CFR 211.198, what corrective action is most critical?

Close all open complaints within 30 days regardless of investigation status
Revise the complaint SOP to exclude minor complaints from investigation
Transfer complaint handling to the marketing department
Establish a complaint trending and investigation system that triggers CAPA for potentially serious complaints (Correct answer)

Correct answer: Establish a complaint trending and investigation system that triggers CAPA for potentially serious complaints

21 CFR 211.198 requires investigation of complaints that could indicate product failure, necessitating a robust system that identifies and investigates potentially serious complaints.

Question 26: What is required in the 'Indications and Usage' section of prescription drug labeling?

The pharmacokinetic profile of the drug
The mechanism of action of the drug
The clinical trial methodology used for approval
A description of the condition(s) for which the drug is approved (Correct answer)

Correct answer: A description of the condition(s) for which the drug is approved

The Indications and Usage section describes the specific disease, condition, or patient population for which FDA has approved the drug.

Question 27: Which concept in regulatory science refers to the use of surrogate endpoints that are 'reasonably likely to predict' clinical benefit, enabling Accelerated Approval?

Composite endpoint
Validated biomarker
Clinical endpoint
Surrogate marker (Correct answer)

Correct answer: Surrogate marker

Accelerated Approval under 21 CFR 601.41/314.510 allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with required post-approval confirmatory trials.

Question 28: What is the purpose of FDA's Expanded Access (compassionate use) program?

It expands FDA's authority to conduct unannounced post-market surveillance inspections
It enables manufacturers to market unapproved drugs after completing post-market studies
It provides patients with serious conditions access to investigational products outside clinical trials (Correct answer)
It allows FDA to expand marketing authorization for post-approval drugs to new indications

Correct answer: It provides patients with serious conditions access to investigational products outside clinical trials

The Expanded Access program allows patients with serious or life-threatening conditions to access investigational drugs or devices when no comparable alternatives exist and enrollment in a clinical trial is not feasible.

Question 29: Under FDA's labeling requirements, which section of a drug's prescribing information must describe potential adverse reactions identified in clinical trials?

Adverse Reactions (Correct answer)
Drug Interactions
Warnings and Precautions
Contraindications

Correct answer: Adverse Reactions

The Adverse Reactions section of the prescribing information is specifically designated to describe undesirable effects observed in clinical trials and post-marketing experience.

Question 30: What is a 'field safety corrective action' (FSCA) in the context of medical devices?

A corrective action performed at the manufacturing facility before distribution
An action taken in response to receiving an FDA warning letter
An action required during pre-market device testing and validation
Any action to reduce a risk of death or serious injury associated with an already-distributed device (Correct answer)

Correct answer: Any action to reduce a risk of death or serious injury associated with an already-distributed device

An FSCA is any action taken by a manufacturer or distributor to reduce the risk of death or serious health deterioration associated with a device already placed on the market.

Question 31: Which FDA regulation requires that design controls for medical devices include risk analysis as part of the design process?

21 CFR Part 820.30 (Correct answer)
21 CFR Part 801
21 CFR Part 814
21 CFR Part 803

Correct answer: 21 CFR Part 820.30

21 CFR Part 820.30 (Design Controls) requires risk analysis as a component of the design and development process for medical devices.

Question 32: A regulatory affairs manager wants to benchmark submission timelines against industry standards. Which publicly available FDA database provides approval timeline data to support this analysis?

FAERS (FDA Adverse Event Reporting System)
FDA Form 483 observation database
Drugs@FDA database and PDUFA performance reports (Correct answer)
USP compendium online portal

Correct answer: Drugs@FDA database and PDUFA performance reports

Drugs@FDA and PDUFA performance reports contain approval dates, review times, and cycle information that can be used to benchmark an organization's submission performance.

Question 33: A medical device company's post-market surveillance (PMS) data reveals a statistically significant increase in a specific user error. Under EU MDR Article 83, the company's PSUR must:

Be submitted immediately to the notified body as a serious incident
Be revised to remove the device from scope pending investigation
Include the trend data, benefit-risk analysis, and any corrective actions taken to address the user error pattern (Correct answer)
Exclude user errors as they are outside the manufacturer's control

Correct answer: Include the trend data, benefit-risk analysis, and any corrective actions taken to address the user error pattern

EU MDR PSURs must include post-market surveillance data findings—including use-error trends—along with benefit-risk reassessment and any actions taken.

Question 34: A drug company's Quality Management Review reveals that the ratio of preventive actions to corrective actions is very low (10:90). What does this indicate about the company's quality culture?

The preventive action process is too burdensome for staff to use
The company is largely reactive rather than proactive in its quality management approach (Correct answer)
The company has very few quality problems
The company has excellent detection systems

Correct answer: The company is largely reactive rather than proactive in its quality management approach

A high corrective-to-preventive action ratio indicates the organization primarily responds to failures after they occur rather than identifying and eliminating potential risks proactively.

Question 35: Under FDA regulations, which outcome qualifies an adverse event as 'serious'?

An event requiring a dosage adjustment
Death, life-threatening condition, hospitalization, disability, or congenital anomaly (Correct answer)
Any event requiring a pharmacy visit
Any event reported by more than 1% of patients in a clinical trial

Correct answer: Death, life-threatening condition, hospitalization, disability, or congenital anomaly

A serious adverse event is defined as one resulting in death, life-threatening conditions, inpatient hospitalization, significant disability, congenital anomaly, or requiring medical intervention to prevent permanent harm.

Question 36: What should a practitioner do when regulations conflict with employer policies?

Follow the regulation, as legal requirements supersede employer policies (Correct answer)
Always follow employer policies
Ignore both and use personal judgment
Follow whichever is easier to comply with

Correct answer: Follow the regulation, as legal requirements supersede employer policies

Legal and regulatory requirements always take precedence over employer policies, and practitioners have a professional obligation to comply with applicable laws.

Question 37: Which FDA office is responsible for regulating direct-to-consumer (DTC) prescription drug advertising?

Federal Trade Commission (FTC)
NIH Office of Consumer Affairs
FDA Division of Drug Information
FDA Office of Prescription Drug Promotion (OPDP) (Correct answer)

Correct answer: FDA Office of Prescription Drug Promotion (OPDP)

The FDA's Office of Prescription Drug Promotion (OPDP) regulates DTC prescription drug advertising to ensure it is truthful and not misleading.

Question 38: Which FDA regulation governs the labeling of over-the-counter (OTC) and prescription drug products?

21 CFR Part 207
21 CFR Part 314
21 CFR Part 600
21 CFR Part 201 (Correct answer)

Correct answer: 21 CFR Part 201

21 CFR Part 201 contains the general labeling requirements applicable to both OTC and prescription drug products.

Question 39: A pharmaceutical company wants to make a labeling change that adds a new warning to an approved NDA. Which submission type is most appropriate?

Annual Report
Changes Being Effected Supplement (Correct answer)
Changes Being Effected in 30 Days
Prior Approval Supplement

Correct answer: Changes Being Effected Supplement

Adding a new warning label to strengthen safety information typically qualifies as a Changes Being Effected (CBE-0) supplement, which can be implemented immediately upon submission.

Question 40: A patient advocacy group requests a briefing on the regulatory status of a product they are following. What should a regulatory affairs professional consider before responding?

Whether the advocacy group has a financial stake in the company
Whether the FDA has approved communication with patient groups at this stage
What information is publicly available versus confidential, and what level of detail is appropriate for the audience (Correct answer)
Whether sharing the information could generate competitor intelligence

Correct answer: What information is publicly available versus confidential, and what level of detail is appropriate for the audience

Communications with patient advocacy groups must balance transparency with confidentiality obligations and be tailored to the lay audience's level of understanding.

Question 41: FDA issues an updated guidance document that narrows acceptable impurity thresholds for a marketed drug. Under 21 CFR Part 314, what is the manufacturer's obligation?

Submit a Field Alert Report within 3 days
Notify FDA within 30 days with no changes required
Assess the impact and file a Prior Approval Supplement if manufacturing changes are needed (Correct answer)
Immediately recall the product

Correct answer: Assess the impact and file a Prior Approval Supplement if manufacturing changes are needed

Changes affecting product quality or specifications in an approved application generally require a supplement, with the type (PAS, CBE-30, Annual) depending on the risk level of the change.

Question 42: A CAPA was initiated after a field complaint involving patient injury. At which stage should risk management documentation be updated?

Only after the CAPA is closed
CAPA does not require updating risk management files
As part of the corrective action planning and implementation process (Correct answer)
During the effectiveness check phase only

Correct answer: As part of the corrective action planning and implementation process

Risk management files should be updated during CAPA implementation to reflect newly identified hazards and the effectiveness of implemented controls.

Question 43: A pharmaceutical company implements a new electronic quality management system (eQMS). Which validation requirement applies under 21 CFR Part 11?

The system must be validated to ensure accuracy, reliability, and consistent performance (Correct answer)
The system must use paper backup for all critical records
Only FDA-approved software platforms may be used
Validation is only required if the system stores batch records

Correct answer: The system must be validated to ensure accuracy, reliability, and consistent performance

21 CFR Part 11 requires that electronic records systems be validated to ensure they accurately and reliably perform their intended functions.

Question 44: Which of the following best describes a corrective action within a CAPA (Corrective and Preventive Action) system?

Investigating a root cause of nonconformance and implementing fixes to prevent recurrence (Correct answer)
Training new employees on standard operating procedures as part of onboarding
Documenting a procedure that was already performed correctly
Performing scheduled routine quality audits on manufacturing processes

Correct answer: Investigating a root cause of nonconformance and implementing fixes to prevent recurrence

A corrective action addresses an identified nonconformance by determining its root cause and implementing process changes to prevent the problem from recurring.

Question 45: Under EU regulations, what does the CE marking on a medical device signify?

The device has been clinically validated
The device is approved by the EMA
The device meets EU health, safety, and environmental requirements (Correct answer)
The device was manufactured in the EU

Correct answer: The device meets EU health, safety, and environmental requirements

CE marking indicates that a product conforms to applicable EU legislation and meets essential safety and performance requirements, allowing free market access across the European Economic Area.

Question 46: What does the 'PLR' format refer to in FDA prescription drug labeling?

Pharmaceutical Literature Registry
Product Liability Report format
Post-Labeling Review process
Physician's Labeling Rule format for structured prescriber labeling (Correct answer)

Correct answer: Physician's Labeling Rule format for structured prescriber labeling

The Physician's Labeling Rule (PLR), effective 2006, restructured prescription drug package inserts into standardized sections to improve usability for healthcare professionals.

Question 47: Under the EU MDR (2017/745), which classification rule typically applies to an implantable device intended to be in long-term contact with the cardiovascular system?

Class III (Correct answer)
Class IIa
Class IIb
Class I

Correct answer: Class III

Under EU MDR, implantable devices in contact with the cardiovascular system or central nervous system are typically classified as Class III due to the highest risk level.

Question 48: What is the primary purpose of a post-implementation review (PIR) after a regulatory-driven process change?

To document the cost of the change for accounting purposes
To satisfy the annual product review requirement under 21 CFR 211.180(e)
To verify that the change achieved its intended outcome without introducing new risks (Correct answer)
To update the master validation plan with completed change history

Correct answer: To verify that the change achieved its intended outcome without introducing new risks

A PIR confirms that implemented changes met their objectives and did not create unintended consequences, closing the PDCA loop.

Question 49: Which FDA office has primary responsibility for coordinating national enforcement actions and issuing Warning Letters for drug GMP violations?

Office of Regulatory Affairs (ORA)
Office of Chief Counsel
Office of Criminal Investigations (OCI)
Center for Drug Evaluation and Research (CDER) Office of Compliance (Correct answer)

Correct answer: Center for Drug Evaluation and Research (CDER) Office of Compliance

CDER's Office of Compliance has primary responsibility for drug enforcement actions, including issuing Warning Letters for GMP and other drug-related violations.

Question 50: A sponsor is developing a biologic and wants to rely on safety and efficacy data from an already-approved reference product. Which application pathway applies?

Biosimilar BLA under 351(k) (Correct answer)
NDA 505(b)(2) with reference to the biologic
Standard BLA under 351(a)
ANDA referencing the reference listed drug

Correct answer: Biosimilar BLA under 351(k)

Section 351(k) of the PHS Act establishes the biosimilar pathway, allowing sponsors to rely on the reference product's safety and efficacy data.

Question 51: What must a Periodic Adverse Drug Experience Report (PADER) include for an NDA holder?

Financial disclosures from clinical investigators involved in trials
A summary of all adverse drug experiences received during the reporting period (Correct answer)
Manufacturing process validation data collected post-approval
Marketing authorization renewal documentation and labeling history

Correct answer: A summary of all adverse drug experiences received during the reporting period

PADERs require NDA holders to submit quarterly and annual summaries of all adverse drug experiences received during the reporting period, including domestic and foreign reports.

Certified Regulatory Affairs Professional (CRAP)

The CRAP certification validates expertise in regulatory affairs including compliance monitoring, labeling regulations, post-market surveillance, enforcement, and global regulatory standards for professionals in regulated industries.

Questions

75 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds